Radium-223 Therapy of Bone Metastases in Prostate Cancer.
Metastatic castration-resistant prostate cancer frequently metastasizes to the bone, often resulting in painful skeletal events, reduced quality of life, and reduced survival. Radium-223 is a first-in-class alpha-emitting radiopharmaceutical that has proven to prolong overall survival, delay time to symptomatic skeletal events, and improve quality of life in patients with castration-resistant prostate cancer and symptomatic bone metastases and no visceral metastases. Radium-223 provides survival benefit to patients with castration-resistant prostate cancer and symptomatic bone metastases, regardless of prior docetaxel use. This article gives an overview of the development of radium-223 from the first-in-human trial to current status.
Department of Oncology and Pathology, Radiumhemmet, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. Electronic address: sten.nilsson@ki.se.
Sten
S
Nilsson
D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D011883:Radium / Q000493:pharmacokinetics / Q000627:therapeutic use*
D011883:Radium